Abstracts tagged "meta-analysis"

Abstract Number: 1202 • ACR Convergence 2020
Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis
Manon Guillouard¹, Nicolas Authier¹, Bruno Pereira¹, Martin Soubrier¹ and Sylvain Mathieu¹, ¹CHU Gabriel Montpied, Clermont-Ferrand, France
Background/Purpose: Despite classic analgesic or effective treatments in rheumatic diseases, such as synthetic Disease Modifying Anti-Rheumatic Drugs in rheumatoid arthritis (RA), patients remain in pain…
Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Adela Castro¹, Jesus Diaz², Guillermo Quiceno³ and John Cush⁴, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…
Abstract Number: 1428 • ACR Convergence 2020
The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Matthew J. Koster¹, Kenneth Warrington¹, Jian Han² and Shalini V. Mohan², ¹Mayo Clinic, Rochester, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) has been proven to be safe and effective for the treatment of giant cell arteritis (GCA) in 2 randomized controlled trials; however,…
Abstract Number: 1452 • ACR Convergence 2020
Transcriptomic Meta-analysis Reveals a Core Transcriptional Program in Murine B Cell Anergy and Implicates Immunometabolic Regulation as a Central Pathway in Maintaining Non-responsiveness of Autoreactive B-cells in Both Mouse and Man
Isaac Harley¹, Bergren Crute², Andrew Getahun² and John Cambier³, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado – Anschutz Medical Campus, Aurora, ³Univ, Aurora
Background/Purpose: The mechanisms self-tolerance loss that lead to autoantibody-mediated autoimmune disease remain underdefined. The rapid reversibility of peripheral B-cell tolerance in murine models suggests that…
Abstract Number: 1547 • ACR Convergence 2020
Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis
Arya Haj-Mirzaian¹, Olga Kubassova², Mikael Boesen³, Paul Bird⁴ and John Carrino⁵, ¹Johns Hopkins Hospital, Baltimore, MD, ²Image Analysis Group, London, United Kingdom, ³Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ⁴Optimus Clinical Research, Kogarah, University of New South Wales, Sydney, New South Wales, Australia, ⁵Hospital for Special Surgery, Hackensack, NJ
Background/Purpose: To summarize the feasibility, reliability, and validity of computer-aided quantification of joint destruction and synovitis on MRI using artificial intelligence (AI) based methods in…
Abstract Number: 1735 • ACR Convergence 2020
Effect of Aerobic Land-based Exercise Intervention on Fatigue in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Samar Aboulenain¹, Arezo Farhangi², Elie Donath¹ and Ozlem Pala³, ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Palm Beach Gardens, FL, ³University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Persistent fatigue can be debilitating for patients with rheumatoid arthritis (RA). Although fatigue partially improves after the initiation of DMARDs, suggesting an inflammatory process,…
Abstract Number: 0010 • ACR Convergence 2020
Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis
Michael Putman¹, Yu Pei Eugenia Chock², Herman Tam³, Alfred Kim⁴, Sebastian Sattui⁵, Francis Berenbaum⁶, Maria (Maio) Danila⁷, Peter Korsten⁸, Catalina Sanchez Alvarez⁹, Jeffrey Sparks¹⁰, Laura Coates¹¹, Candace Palmerlee¹², Andrea Pierce¹³, Arundathi Jayatilleke¹⁴, Sindhu Johnson¹⁵, Adam Kilian¹⁶, Jean Liew¹⁷, Larry Prokop⁹, Hassan Murad⁹, Rebecca Grainger¹⁸, Zachary Wallace¹⁹ and Ali Duarte-Garcia⁹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Greenwich, CT, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Washington University School of Medicine, St. Louis, MO, ⁵Hospital for Special Surgery, New York, NY, ⁶Sorbonne Universit�, Paris, France, ⁷University of Alabama at Birmingham (UAB), Birmingham, AL, ⁸University Medical Center Göttingen, Gottingen, Germany, ⁹Mayo Clinic, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Oxford, Oxford, United Kingdom, ¹²12. Patient Research Partner, Berkeley, CA, ¹³Patient Research Partner, New York City, ¹⁴Lewis Katz School of Medicine, Temple University, Philadelphia, PA, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶George Washington University, Washington, DC, ¹⁷University of Washington, Seattle, WA, ¹⁸University of Otago, Wellington, New Zealand, ¹⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. There has been particular interest in the antimalarial agent…
Abstract Number: 0156 • ACR Convergence 2020
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Wojciech Tański¹, Mariusz Chabowski², Natalia Świątoniowska-Lonc³ and Beata Jankowska-Polańska³, ¹4th Military Teaching Hospital, Wrocław, Poland, ²4th Military Teaching Hospital, Wroclaw Medical University, Wrocław, Poland, ³Wroclaw Medical University, Wrocław, Poland
Background/Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease involving the axial skeleton, entheses and peripheral joints, and may occur together with extra-articular manifestations, such…
Abstract Number: 0659 • ACR Convergence 2020
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Megan Leask¹, Nicola Dalbeth², Lisa Stamp³, Tony Merriman⁴, Amanda Phipps-Green⁴, Ruth Topless⁴, James Boocock⁵, Hyon Choi⁶, Keresoma Leaupepe¹ and Eli Stahl⁷, ¹University of Otago, Dunedin, Otago, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago Christchurch, Christchurch, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁷Mt Sinai School of Medicine, New York, NY
Background/Purpose: Polynesian (NZ Māori and Pacific) populations have increased prevalence of gout. Hyperuricaemia is contributed to by increased urate production in the liver via the…
Abstract Number: 0764 • ACR Convergence 2020
Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
Dmitry Rychkov¹, Jessica Neely¹ and Marina Sirota¹, ¹UCSF, San Francisco, CA
Background/Purpose: There is an urgent need to develop objective biomarkers for early diagnosis and monitoring of disease activity in Rheumatoid arthritis (RA). Here we define…
Abstract Number: 0797 • ACR Convergence 2020
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Adela Castro¹, Jesus Diaz² and Guillermo Quiceno³, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Janus Kinase (JAK) inhibitors have shown long term benefit in patients with active RA with inadequate response to conventional or biologic DMARDs (1). Due to…
Abstract Number: 0807 • ACR Convergence 2020
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Akhil Sood¹, Soham Al Snih¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Recent developments in biologic and targeted therapy have led to better control of disease activity and improved quality of life in patients with rheumatoid…
Abstract Number: 1007 • ACR Convergence 2020
Atopic Dermatitis and Risk of Incident Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Thanitsara Rittiphairoj¹, Nipith Charoenngam¹, Ben Ponvilawan¹, Surapa Tornsatitkul¹, Phuuwadith Wattanachayakul¹, Pongprueth Rujirachun¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Recent observational studies have suggested that patients with atopic dermatitis (AD) may have a higher risk of several non IgE-mediated inflammatory disorders, such as…
Abstract Number: 498 • 2019 ACR/ARP Annual Meeting
Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Barbara Mascialino¹ and Teresa Tarrant ², ¹Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, ²Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC
Background/Purpose: The 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis (RA) are based on a combination of clinical, laboratory, and imaging investigations. Positive serology contributes to…
Abstract Number: 1319 • 2019 ACR/ARP Annual Meeting
Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis
stéphanie Ferrero¹, marion louvois ¹, Thomas Barnetche ², Thao Pham ³, Véronique Breuil ¹ and christian roux ⁴, ¹University of Nice, nice, France, ²FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ³Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁴CHU Pasteur Nice, Nice, France
Background/Purpose: Background: The development of knee's osteoarthritis after anterior cruciate ligament ACL injury is now widely recognized. The impact of surgical or rehabilitative management on…

« Previous Page
1
…
4
5
6
7
8
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].